Forecast

Buy	4
Hold	0
Sell	0

News Go to news feed

MediciNova adjusts employment contracts for CEO and CMO

MediciNova approved new employment agreements for President/CEO Dr. med. Dr. Yuichi Iwaki and CMO Dr. med. Dr. Kazuko Matsuda effective August 17, 2026, providing fixed annual salaries of $690,246 (Iwaki) and $540,143 (Matsuda) and performance-based annual bonuses (target: 55% and 40% of base salary, respectively). Both contracts replace prior arrangements, include severance payments for involuntary termination without cause and tiered, substantially higher payouts plus accelerated equity vesting for terminations related to a change of control; they also include a one-year post-contract non-solicitation clause and are governed by Delaware law. Despite 584% revenue growth last year, MediciNova remains unprofitable; analysts' price targets range from $6 to $11. » More on de.investing.com
MediciNova reaches recruitment target of 200 patients for SEANOBI-ALS study

MediciNova reports that the SEANOBI-ALS study of MN-166 (Ibudilast) has reached its recruitment target of 200 patients under the Expanded Access Program. The study is funded by the National Institute of Neurological Disorders and Stroke and the NIH under the "ACT for ALS" program; final follow-ups are expected to conclude in early 2027 and trigger the start of data analysis. MN-166 is an orally active PDE4 and cytokine inhibitor with orphan and Fast Track designations, and analyst price targets for the stock range from $6 to $11, well above the current share price of $1.37. » More on de.investing.com
MediciNova files preliminary, unaudited 2025 annual results in Tokyo

MediciNova has filed preliminary, unaudited financial results for the fiscal year ended December 31, 2025, as part of Japan’s Kessan Tanshin, and notes that the figures may change materially upon completion of the annual audit. The independent auditor has not completed its review and has not issued an opinion or assurance on the preliminary results. In addition, MediciNova reports completion of patient recruitment for the Phase‑2b/3 COMBAT‑ALS trial of MN‑166, a mid‑point in the SEANOBI study, and completion of the OXTOX study; it also entered into a $50 million equity distribution agreement with Lucid Capital Markets. » More on de.investing.com

Financials

In the last quarter, Medicinova had revenue of 401,69k€ and net profit of −2,03 Mio€

(EUR)	Jun 2026	YoY
Revenue	+401,69k	251,75%
Gross profit	+278,42k	1.698,18%
Net profit	−2,03 Mio	27,16%
EBITDA	−2,22 Mio	20,05%

Fundamentals

Metric	Value
Market capitalization	+60,01 Mio€
Number of shares	49,22 Mio
52-week high/low	+1,68€ - +1,00€
Dividends	No
Beta	0,62
P/E ratio	−6,54
PEG ratio	−0,75
P/B ratio	+1,88
P/S ratio	+75,93

Company profile

MediciNova, Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger und niedermolekularer Therapeutika für die Behandlung schwerer Krankheiten mit ungedecktem medizinischem Bedarf in den Vereinigten Staaten konzentriert. Das Unternehmen entwickelt MN-166 (Ibudilast), ein orales entzündungshemmendes und neuroprotektives Mittel zur Behandlung neurologischer Erkrankungen wie primäre und sekundäre progressive Multiple Sklerose, amyotrophe Lateralsklerose, durch Chemotherapie verursachte periphere Neuropathie, degenerative zervikale Myelopathie, Glioblastom sowie Substanzabhängigkeit und Sucht. Die Produktpipeline des Unternehmens umfasst außerdem MN-221 (Bedoradrin), einen selektiven Beta-2-Adrenorezeptor-Agonisten zur Behandlung akuter Exazerbationen von Asthma; MN-001 (Tipelukast), einen oral bioverfügbaren niedermolekularen Wirkstoff zur Behandlung fibrotischer Erkrankungen, einschließlich nichtalkoholischer Steatohepatitis und idiopathischer Lungenfibrose; und MN-029 (Denibulin), ein Tubulin-Bindemittel zur Behandlung von soliden Tumoren. Das Unternehmen hat Kooperationsvereinbarungen mit Kissei Pharmaceutical Co., Ltd; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd; und Meiji Seika Kaisha Ltd. MediciNova, Inc. wurde im Jahr 2000 gegründet und hat seinen Hauptsitz in La Jolla, Kalifornien.